BIOMAT Database Logo BIOMAT Database Logo

Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. 2007

A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007249 Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. Innate Inflammatory Response,Inflammations,Inflammatory Response, Innate,Innate Inflammatory Responses
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005260 Female Females
D005905 Glyburide An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide Glibenclamide,Daonil,Diabeta,Euglucon 5,Euglucon N,Glybenclamide,HB-419,HB-420,Maninil,Micronase,Neogluconin,HB 419,HB 420,HB419,HB420
D005907 Gliclazide An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion. Diabrezide,Diaglyk,Diaikron,Diamicron,Gen-Gliclazide,Gliklazid,Glyade,Glyclazide,Novo-Gliclazide,S-1702,S-852,Gen Gliclazide,Novo Gliclazide,S 1702,S 852,S1702,S852

Related Publications

A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
August 2015, Canadian journal of diabetes,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
The hypoglycemic risk of glyburide (glibenclamide) compared with modified-release gliclazide.
November 2015, Canadian journal of diabetes,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction.
July 2011, The journal of sexual medicine,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes.
August 2004, Journal of internal medicine,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
November 2004, Diabetes, obesity & metabolism,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes.
June 2011, European journal of pharmacology,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
December 1994, Diabetic medicine : a journal of the British Diabetic Association,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
October 2003, Diabetes research and clinical practice,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients.
October 2010, Endocrine,
A Räkel, and G Renier, and A Roussin, and J Buithieu, and J-C Mamputu, and O Serri
Effects of walking on low-grade inflammation and their implications for Type 2 Diabetes.
January 2015, Preventive medicine reports,
Copied contents to your clipboard!